Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.58 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20853476 | 1.00 | OPRM1 (0.58) | OPRM1OPRD1DPP4F2 | |
| SCHEMBL18094994 | 1.00 | OPRM1 (0.58) | OPRM1OPRD1DPP4F2 | |
| SCHEMBL31230863 | 1.00 | OPRM1 (0.58) | OPRM1OPRD1DPP4F2 | |
| Hydrochloric Acid SCHEMBL16703240 | 0.99 | OPRM1 (0.58) | OPRM1OPRD1DPP4F2 | |
| Hydrochloric Acid SCHEMBL28391503 | 0.99 | OPRM1 (0.58) | OPRM1OPRD1DPP4F2 | |
| Hydrochloric Acid SCHEMBL18094991 | 0.99 | OPRM1 (0.58) | OPRM1OPRD1DPP4F2 | |
| Hydrochloric Acid SCHEMBL18094975 | 0.99 | OPRM1 (0.58) | OPRM1OPRD1DPP4F2 | |
| SCHEMBL16703340 | 0.95 | DPP4 (0.54) | OPRM1OPRD1DPP4F2 | |
| SCHEMBL20853463 | 0.95 | DPP4 (0.54) | OPRM1OPRD1DPP4F2 | |
| SCHEMBL16703025 | 0.95 | DPP4 (0.54) | OPRM1OPRD1DPP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4001272-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2024-11-13 | — | — | EP | claimed |
| EP-4001272-A1 | NMDA ANTAGONIST PRODRUGS | Astrazeneca AB (SE) | 2022-05-25 | — | — | EP | claimed |
| EP-3564234-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2021-09-29 | — | — | EP | claimed |
| EP-3564234-A1 | NMDA ANTAGONIST PRODRUGS | AstraZeneca AB (SE) | 2019-11-06 | — | — | EP | claimed |
| EP-3066091-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2019-04-03 | — | — | EP | claimed |
| US-20180037550-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2018-02-08 | — | — | US | claimed |
| US-9822075-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2017-11-21 | — | — | US | claimed |
| US-20160280647-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2016-09-29 | — | — | US | claimed |
| EP-3066091-A1 | NMDA ANTAGONIST PRODRUGS | Astrazeneca AB (SE) | 2016-09-14 | — | — | EP | claimed |
| WO-2015067923-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2015-05-14 | — | — | WO | claimed |
| US-12516023-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2026-01-06 | — | — | US | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| EP-4001272-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2024-11-13 | — | — | EP | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-4001272-A1 | NMDA ANTAGONIST PRODRUGS | Astrazeneca AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| US-20160280647-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2016-09-29 | — | — | US | disclosed |
| US-20160280647-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2016-09-29 | — | — | US | disclosed |
| EP-3066091-A1 | NMDA ANTAGONIST PRODRUGS | Astrazeneca AB (SE) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015067923-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015067923-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280647-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | OPRM1 24/4885OPRD1 29/4885DPP4 1168/4885 |
| US-20180037550-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | OPRM1 24/4885OPRD1 29/4885DPP4 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.